Kiyatec Publishes Study on 3D Predict Glioma for High-Grade Glioma Patients

Kiyatec, based in Greenville, S.C., has announced the publication of a groundbreaking study in Scientific Reports, which underscores the efficacy of their 3D Predict Glioma test in improving survival outcomes for patients with high-grade glioma (HGG). The study, titled "Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma," provides strong evidence that the test can accurately predict patients' responses to the standard chemotherapeutic regimen, thereby significantly extending both progression-free survival and overall survival.

High-grade gliomas, which include glioblastoma (GBM), are notorious for being some of the most aggressive and lethal brain cancers. Traditionally, treatment options have been limited, leading to generally poor prognoses for patients. Despite advancements in understanding these tumors, most treatment strategies have remained static, often involving a uniform approach that includes radiation and the chemotherapy drug temozolomide (TMZ). Kiyatec's 3D Predict Glioma test offers a breakthrough by assessing how a patient’s tumor tissue responds to chemotherapy drugs, including TMZ, before starting the treatment.

Dr. Analiz Rodriguez, a lead author of the study and Director of Neurosurgical Oncology at the University of Arkansas for Medical Sciences, emphasized the significance of the 3D Predict Glioma test. "Our study demonstrates that the 3D Predict Glioma test is not just a prognostic tool but also a crucial decision-making aid for clinicians treating high-grade gliomas," Rodriguez stated. She noted that patients whose tumors were predicted to respond to TMZ using this test experienced considerably longer progression-free and overall survival compared to those who were predicted not to respond. Rodriguez added that the test could potentially outperform current clinical biomarkers used in the standard of care, marking a significant shift in the treatment paradigm for glioma patients.

The prospective, observational study involved 102 patients with newly diagnosed HGG from multiple centers across the United States. Results showed that patients identified as responders by the 3D Predict Glioma test had a median increase of 5.8 months in progression-free survival and 7.6 months in overall survival compared to nonresponders. These improvements were observed consistently across various subgroups, including GBM and MGMT unmethylated glioblastoma, a particularly difficult subgroup to treat.

One of the notable findings of the study was that the test’s predictive ability was independent of traditional biomarkers like MGMT promoter methylation, which has been a standard in guiding glioma treatment for the past two decades. This highlights the potential of the 3D Predict Glioma test to offer a more detailed and accurate prediction of patient outcomes, enabling more personalized treatment plans. Such precision could help patients avoid ineffective treatments and direct them toward more promising therapeutic options, including clinical trials.

Eric Perreault, the CEO of Kiyatec, remarked on the significant milestone represented by the study’s publication. "Our 3D Predict Glioma test is pioneering a new era of individualized treatment for patients with high-grade glioma, providing hope where it was previously scarce," Perreault stated.

Kiyatec specializes in functional precision oncology, with their innovative 3D Predict technology delivering patient-specific predictions of drug response. This enables oncologists to make well-informed treatment decisions. Currently, Kiyatec offers clinical testing for high-grade glioma and plans to expand testing to include ovarian cancer in their CLIA-certified laboratory. The company's mission is to empower patients and oncologists with actionable insights for making critical cancer therapy decisions through advanced ex vivo testing solutions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!